Hikma Pharmaceuticals Public annual diluted eps
Diluted EPSBasic EPS
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public EPS History: Annual & Quarterly (HIK)
Hikma Pharmaceuticals Public's diluted EPS was $1.81 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.81 | $1.82 | $0.20 | +12.42% |
| 2024 | 2024-12-31 | $1.61 | $1.62 | $0.76 | +89.41% |
| 2023 | 2023-12-31 | $0.85 | $0.86 | $0.01 | +1.19% |
| 2022 | 2022-12-31 | $0.84 | $0.84 | -$0.97 | −53.51% |
| 2021 | 2021-12-31 | $1.81 | $1.82 | -$0.00 | −0.22% |
| 2020 | 2020-12-31 | $1.81 | $1.83 | — | — |
Hikma Pharmaceuticals Public diluted eps trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's diluted eps decreased from $1.81 to $1.81, a change of -$0.00.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from official filings. Historical EPS values are adjusted to the current share basis when reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...